We recently compiled a list of the Top 12 Stocks to Buy According to Bourgeon Capital. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other ...

Davis, Chairman and CEO, Merck. Founded in 1891, Merck (NYSE:MRK) is a global pharmaceutical company that develops prescription medicines, vaccines, biologic therapies, and animal health products.

Is now the time to initiate a position? Find out in our full research report, it’s free. Founded in 1891, Merck (NYSE:MRK) is a global pharmaceutical company that develops prescription medicines, ...

The shares were sold at a weighted average price of $61.1891, resulting in a total transaction ... and potential European Union launch in 2025. Merck (NSE:PROR) KGaA is in advanced discussions ...

The stock is down 3.1% since reporting and currently trades at $61.46. Founded in 1891, Merck (NYSE:MRK) is a global pharmaceutical company that develops prescription medicines, vaccines ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

Trial adjourned, new jury due to reconvene in September Kennedy helped organize litigation against Merck before HHS role Merck denies claims, cites scientific evidence supporting Gardasil safety ...

Biotech Halozyme Therapeutics believes the new version of Merck's blockbuster cancer drug Keytruda infringes on its patents, the Wall Street Journal reported on Wednesday (March 5, 2025), citing ...

It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates ...